Hyperfine, Inc. (HYPR): R&D Expense
$17.45M
Year ended 2025-12-31
$15.58M
Trailing 12 months to 2026-06-30
-14.7%
3-year compound annual growth
+3.6%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $17.45M | -22.4% | 2026-03-18, From 2025-01-01 |
| 2024-12-31 | $22.50M | 0.0% | 2026-03-18, From 2024-01-01 |
| 2023-12-31 | $22.49M | -20.1% | 2025-03-17, From 2023-01-01 |
| 2022-12-31 | $28.16M | +9.0% | 2024-03-22, From 2022-01-01 |
| 2021-12-31 | $25.84M | +77.1% | 2023-03-22, From 2021-01-01 |
| 2020-12-31 | $14.59M | n/a | 2022-03-25, From 2020-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Hyperfine, Inc. (HYPR) | 2025-12-31 | $17.45M | -22.4% |
| CapsoVision, Inc (CV) | 2025-12-31 | $18.31M | +21.1% |
| Escalon Medical Corp (ESMC) | 2025-06-30 | $753.1K | +9.4% |
| QT Imaging Holdings, Inc. (QTI) | 2025-12-31 | $3.94M | +20.5% |
| Precision Optics Corporation, Inc. (POCI) | 2025-06-30 | $1.16M | +17.9% |
| Nuwellis, Inc. (NUWE) | 2025-12-31 | $2.71M | -15.5% |
| electroCore, Inc. (ECOR) | 2024-12-31 | $2.36M | -55.6% |
| Stereotaxis, Inc. (STXS) | 2025-12-31 | $9.38M | -3.9% |
| Neuraxis, Inc (NRXS) | 2025-12-31 | $493.6K | +13.8% |
Compare HYPR, CV, ESMC, QTI side by side · Screen every company in Electromedical & Electrotherapeutic Apparatus ↗